

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

DAIICHI SANKYO to Dissolve Subsidiaries with Sanofi-aventis

Tokyo, October 31, 2008 – DAIICHI SANKYO COMPANY, LIMITED has announced that the dissolution of its subsidiaries Laboratoire Daiichi Sanofi-aventis (hereinafter LDS) and Sanofi-aventis Daiichi Pharmaceutical (hereinafter SDC) have been approved at the board of directors meeting held today. The impact of this dissolution on the earnings of DAIICHI SANKYO of the fiscal year ending March 2009 will be negligible.

DAIICHI SANKYO and Sanofi-aventis (Headquarters: Paris, France) established the joint ventures LDS and SDC in 1989 with the objective of developing pharmaceuticals for treatment of thrombotic disease. The dissolution of LDS and SDC was agreed upon by both companies in 2005. With post-dissolution procedures now possible, LDS is to be dissolved on January 13, 2009 and SDC is to be dissolved on December 26, 2008.

About Laboratoires Daiichi Sanofi-aventis

Date established: December 22, 1989
Headquarters: Paris, France
President and Representative Director: Kiyoshi Morita
Main business: Development of pharmaceutical products for treatment of thrombotic disease

About Sanofi-aventis Daiichi Pharmaceutical Company, Limited

Date established: October 16, 1989
Headquarters: Tokyo, Japan
President and Representative Director: Patrick Chocat
Main business: Development of pharmaceutical products for treatment of thrombotic disease